Hi again,

Le 17/06/2023 à 22:14, Pierre Gruet a écrit :
Hi all,

Le 17/06/2023 à 19:37, Nilesh Patra a écrit :
On 06/17/2023 11:21 AM IST Andreas Tille <andr...@an3as.eu> wrote:
'''
1.10. "Research Purposes" means use for internal research and not intended for or directed towards commercial advantages or monetary compensation; provided, however, that monetary compensation does not include sponsored
research of research funded by grants.
'''

What about opening an upstream to the consequence that this change of
the license will remove the package from Debian.

That's a sensible thing to do, but I will not do it. I see my time spent well on packaging instead of engaging with upstream in matters that are /not/ technical, and I have no interest to pursue the
same in this case either.
If you or anybody else would like to ask upstream about reconsidering their license, that's be great.

I only wanted to draw the attention to not go ahead with a pychopper update (to 2.7.4) at the moment.

[1] https://wiki.debian.org/DebianMed/SoftwareLiberation

I opened an issue [2] and marked it in [1]. Let's see...

[2] https://github.com/epi2me-labs/pychopper/issues/27

Updates: upstream answered they would not revert to a DFSG-free license, although the given reasons do not seem to address our concern, as tmancill also pointed out in the Github issue [2].

Meanwhile, I updated the package in Debian to version 2.7.3, which is the last one under MPL-2.0. I dropped a note in debian/README.source about the licensing issue.

Best,

--
Pierre

Attachment: OpenPGP_signature
Description: OpenPGP digital signature

Reply via email to